Passage Bio (NASDAQ:PASG – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a report released on Thursday,Benzinga reports. They currently have a $7.

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) this week reported its third quarter financial results for 2024, ...

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Passage Bio (PASG – Research Report) yesterday and set a price target ...

Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort ...

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that Will Chou, M.D., the president and chief executive officer ...

PHILADELPHIA - Passage Bio, Inc. (NASDAQ:PASG), a genetic medicines company, presented promising preclinical and interim clinical data for its gene therapy product, PBFT02, at the... PHILADELPHIA ...

Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and ...

Traders use this information to analyze potential trades and assess market sentiment for Passage Bio. In The Money Expiration Date November 15, 2024 December 20, 2024 March 21, 2025 June 20, 2025 ...

“This quarter, we've made important strides in advancing our PBFT02 gene therapy program,” said Will Chou, M.D., president and chief executive officer of Passage Bio.“Execution of our ...

PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative ...